With Doctor Robert Ballotti and Professor Jean-Paul Ortonne, both hospital dermatologists and researchers at a large French institute, CEBELIA, an expert in patented treatments for aesthetic medicine, participated in very innovative work to patent a new regulator melanogenesis and fight against skin hyperpigmentation.

Normal skin pigmentation is mainly due to melanin. Melanocytes are the cells of the epidermis responsible for the synthesis of melanin through the phenomenon of melanogenesis, and provide a protective role against UV rays. Under the effect of UV rays, in skin in good working order, hormones and enzymes (&MSH, PKA, tyrosinase, etc.) stimulate the production of melanin.

This production of pigments is retained in bags, the melanosomes, then sent to the upper layers of the epidermis. This is the tanning phenomenon which is normally uniform. Skin hyperpigmentation can be due either to the abnormal presence in the skin of a pigment of endogenous or exogenous origin (medications, etc.) or to an accumulation or a distribution disorder of melanin (exposure to the sun, hormonal disorders, etc.). ).

Discover our solution, a patented depigmenting active ingredient that reduces the level of melanin within your cells.
In order to act on the overall process of melanogenesis, we have selected a patented active ingredient, Pekaline, which acts on two levels:

1. A protein kinase A (PKA) inhibitor, it blocks transcription of the tyrosinase gene and therefore melanin synthesis.
2. It modifies the intramelanosomal pH which plays a crucial role in the control of melanogenesis. The pH inside the melanosomes becomes acidic (pH < 7) which inhibits melanogenesis.

It causes a blockage of melanin synthesis inside cells by inhibition of protein kinase (PKA) and pigment maturation (acidic pH).